HC Wainwright Reiterates “Buy” Rating for Solid Biosciences (NASDAQ:SLDB)

HC Wainwright restated their buy rating on shares of Solid Biosciences (NASDAQ:SLDB) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $16.00 target price on the stock.

Several other brokerages have also issued reports on SLDB. Barclays reduced their target price on shares of Solid Biosciences from $18.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. William Blair raised shares of Solid Biosciences to a “strong-buy” rating in a report on Friday, August 30th. Finally, JPMorgan Chase & Co. raised Solid Biosciences from a “neutral” rating to an “overweight” rating and increased their price target for the company from $10.00 to $15.00 in a research note on Monday, July 15th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Solid Biosciences has a consensus rating of “Buy” and a consensus target price of $15.67.

Solid Biosciences Trading Up 1.7 %

NASDAQ:SLDB opened at $5.87 on Thursday. Solid Biosciences has a 1 year low of $2.00 and a 1 year high of $15.05. The firm has a 50 day moving average of $6.84 and a 200-day moving average of $7.75.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.12). On average, equities research analysts predict that Solid Biosciences will post -2.75 earnings per share for the current year.

Institutional Trading of Solid Biosciences

Large investors have recently made changes to their positions in the company. Point72 DIFC Ltd bought a new stake in Solid Biosciences during the 2nd quarter worth approximately $58,000. Ground Swell Capital LLC bought a new stake in shares of Solid Biosciences during the second quarter worth $76,000. Algert Global LLC acquired a new stake in shares of Solid Biosciences during the second quarter worth $82,000. Susquehanna Fundamental Investments LLC bought a new stake in Solid Biosciences in the 2nd quarter valued at $92,000. Finally, Quantum Private Wealth LLC acquired a new position in Solid Biosciences in the 3rd quarter worth $220,000. Institutional investors own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.